Literature DB >> 33927375

Metabolic barriers to cancer immunotherapy.

Kristin DePeaux1,2, Greg M Delgoffe3,4.   

Abstract

Several non-redundant features of the tumour microenvironment facilitate immunosuppression and limit anticancer immune responses. These include physical barriers to immune infiltration, the recruitment of suppressive immune cells and the upregulation of ligands on tumour cells that bind to inhibitory receptors on immune cells. Recent insights into the importance of the metabolic restrictions imposed by the tumour microenvironment on antitumour T cells have begun to inform immunotherapeutic anticancer strategies. Therapeutics that target metabolic restrictions, such as low glucose levels, a low pH, hypoxia and the generation of suppressive metabolites, have shown promise as combination therapies for different types of cancer. In this Review, we discuss the metabolic aspects of the antitumour T cell response in the context of immune checkpoint blockade, adoptive cell therapy and treatment with oncolytic viruses, and discuss emerging combination strategies.
© 2021. Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33927375      PMCID: PMC8553800          DOI: 10.1038/s41577-021-00541-y

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  201 in total

Review 1.  Metabolic Barriers to T Cell Function in Tumors.

Authors:  Ayaka Sugiura; Jeffrey C Rathmell
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

2.  Inhibitory effect of tumor cell-derived lactic acid on human T cells.

Authors:  Karin Fischer; Petra Hoffmann; Simon Voelkl; Norbert Meidenbauer; Julia Ammer; Matthias Edinger; Eva Gottfried; Sabine Schwarz; Gregor Rothe; Sabine Hoves; Kathrin Renner; Birgit Timischl; Andreas Mackensen; Leoni Kunz-Schughart; Reinhard Andreesen; Stefan W Krause; Marina Kreutz
Journal:  Blood       Date:  2007-01-25       Impact factor: 22.113

3.  The nutrient environment affects therapy.

Authors:  Alexander Muir; Matthew G Vander Heiden
Journal:  Science       Date:  2018-06-01       Impact factor: 47.728

Review 4.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

5.  CD19 CAR T Cells.

Authors:  Michel Sadelain
Journal:  Cell       Date:  2017-12-14       Impact factor: 41.582

6.  Restoring function in exhausted CD8 T cells during chronic viral infection.

Authors:  Daniel L Barber; E John Wherry; David Masopust; Baogong Zhu; James P Allison; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Nature       Date:  2005-12-28       Impact factor: 49.962

7.  Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

Authors:  Shannon L Maude; Theodore W Laetsch; Jochen Buechner; Susana Rives; Michael Boyer; Henrique Bittencourt; Peter Bader; Michael R Verneris; Heather E Stefanski; Gary D Myers; Muna Qayed; Barbara De Moerloose; Hidefumi Hiramatsu; Krysta Schlis; Kara L Davis; Paul L Martin; Eneida R Nemecek; Gregory A Yanik; Christina Peters; Andre Baruchel; Nicolas Boissel; Francoise Mechinaud; Adriana Balduzzi; Joerg Krueger; Carl H June; Bruce L Levine; Patricia Wood; Tetiana Taran; Mimi Leung; Karen T Mueller; Yiyun Zhang; Kapildeb Sen; David Lebwohl; Michael A Pulsipher; Stephan A Grupp
Journal:  N Engl J Med       Date:  2018-02-01       Impact factor: 91.245

8.  THE METABOLISM OF TUMORS IN THE BODY.

Authors:  O Warburg; F Wind; E Negelein
Journal:  J Gen Physiol       Date:  1927-03-07       Impact factor: 4.086

9.  Acidic extracellular microenvironment and cancer.

Authors:  Yasumasa Kato; Shigeyuki Ozawa; Chihiro Miyamoto; Yojiro Maehata; Atsuko Suzuki; Toyonobu Maeda; Yuh Baba
Journal:  Cancer Cell Int       Date:  2013-09-03       Impact factor: 5.722

10.  Oncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model.

Authors:  Eonju Oh; Il-Kyu Choi; JinWoo Hong; Chae-Ok Yun
Journal:  Oncotarget       Date:  2017-01-17
View more
  52 in total

1.  D2HGDH-mediated D2HG catabolism enhances the anti-tumor activities of CAR-T cells in an immunosuppressive microenvironment.

Authors:  Quanjun Yang; Juan Hao; Mengyi Chi; Yaxian Wang; Jie Li; Jinlu Huang; Jianping Zhang; Mengqi Zhang; Jin Lu; Shumin Zhou; Ting Yuan; Zan Shen; Shuier Zheng; Cheng Guo
Journal:  Mol Ther       Date:  2022-01-07       Impact factor: 11.454

Review 2.  Payload Delivery: Engineering Immune Cells to Disrupt the Tumour Microenvironment.

Authors:  Daniel Fowler; Callum Nattress; Alba Southern Navarrete; Marta Barisa; Jonathan Fisher
Journal:  Cancers (Basel)       Date:  2021-11-29       Impact factor: 6.639

Review 3.  Metabolic communication in the tumour-immune microenvironment.

Authors:  Kung-Chi Kao; Stefania Vilbois; Chin-Hsien Tsai; Ping-Chih Ho
Journal:  Nat Cell Biol       Date:  2022-10-13       Impact factor: 28.213

4.  Intracellular Acetyl CoA Potentiates the Therapeutic Efficacy of Antitumor CD8+ T Cells.

Authors:  Anwesha Kar; Debaleena Bhowmik; Snehanshu Chowdhury; Anupam Gautam; Debashree Basak; Ishita Sarkar; Puspendu Ghosh; Deborpita Sarkar; Alvina Deka; Paramita Chakraborty; Asima Mukhopadhyay; Shikhar Mehrotra; Soumen Basak; Sandip Paul; Shilpak Chatterjee
Journal:  Cancer Res       Date:  2022-07-18       Impact factor: 13.312

5.  Synergistic Therapeutic Effects of Low Dose Decitabine and NY-ESO-1 Specific TCR-T Cells for the Colorectal Cancer With Microsatellite Stability.

Authors:  Ganjun Yu; Wenying Wang; Xiaobo He; Jia Xu; Rongrong Xu; Tao Wan; Yanfeng Wu
Journal:  Front Oncol       Date:  2022-06-14       Impact factor: 5.738

6.  An in situ hydrogel-mediated chemo-immunometabolic cancer therapy.

Authors:  Bo Wang; Jing Chen; Julia S Caserto; Xi Wang; Minglin Ma
Journal:  Nat Commun       Date:  2022-07-02       Impact factor: 17.694

7.  ARL4C Regulates the Progression of Clear Cell Renal Cell Carcinoma by Affecting the Wnt/β-Catenin Signaling Pathway.

Authors:  Peizhi Zhang; Yingkun Xu; Shaoan Chen; Zicheng Wang; Leizuo Zhao; Chen Chen; Weiting Kang; Rongyu Han; Jiechuan Qiu; Qingliang Wang; Han Gao; Guangzhen Wu; Qinghua Xia
Journal:  J Oncol       Date:  2022-06-21       Impact factor: 4.501

8.  ACYP1 Is a Pancancer Prognostic Indicator and Affects the Immune Microenvironment in LIHC.

Authors:  Lingyi Zhou; Zheng Fu; Shuai Wang; Jing Jia; Yumeng Cheng; Yunxiang Zheng; Ningning Zhang; Wei Lu; Zhi Yao
Journal:  Front Oncol       Date:  2022-05-02       Impact factor: 5.738

Review 9.  Clinical translation of immunomodulatory therapeutics.

Authors:  Amanda Nash; Samira Aghlara-Fotovat; Andrea Hernandez; Christopher Scull; Omid Veiseh
Journal:  Adv Drug Deliv Rev       Date:  2021-07-27       Impact factor: 17.873

10.  Immunology of Cell Death in Cancer Immunotherapy.

Authors:  Lorenzo Galluzzi; Abhishek D Garg
Journal:  Cells       Date:  2021-05-15       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.